METTL3-dependent m6A modification mediates bladder remodeling after partial bladder outlet obstruction through CCN2...

Area of Science:

• Epigenetics
• Molecular Biology
• Urology

Background:

• N6-methyladenosine (m6A) modification is a key posttranscriptional regulator.
• m6A modifications are implicated in various diseases, including cancer.
• Understanding m6A in partial bladder outlet obstruction (pBOO) and bladder remodeling is crucial for therapeutic development.

Purpose of the Study:

• To characterize the m6A modification landscape in pBOO.
• To investigate the drivers of bladder remodeling in pBOO.
• To identify potential pharmaceutical targets for pBOO therapies.

Main Methods:

• An improved rat model of pBOO was established.
• Urodynamic and cystometric evaluations assessed bladder function.
• Whole-transcriptome (RNA-seq) and m6A-seq (MeRIP-seq) analyzed gene expression patterns.

Main Results:

• pBOO induced significant increases in bladder pressure-related parameters.
• Bladder remodeling was confirmed histologically.
• Global m6A RNA methylation and METTL3 expression were elevated in pBOO.
• Differential gene expression patterns were identified between pBOO and sham groups.
• CCN2 was identified as a potential m6A-modified therapeutic target.

Conclusions:

• m6A modification plays a role in pBOO-induced bladder remodeling.
• Integrating RNA-seq and MeRIP-seq data reveals key m6A-modified genes.
• Targeting m6A-modified genes offers novel therapeutic avenues for pBOO.